iBio, Inc. (NASDAQ:IBIO – Free Report) – Brookline Capital Markets increased their FY2027 earnings per share estimates for shares of iBio in a research report issued on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.29) for the year, up from their previous estimate of ($0.31). The consensus estimate for iBio’s current full-year earnings is ($0.39) per share. Brookline Capital Markets also issued estimates for iBio’s Q4 2027 earnings at ($0.09) EPS.
iBio (NASDAQ:IBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $0.03 million.
Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded iBio from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a report on Monday, September 21st. Finally, HC Wainwright started coverage on shares of iBio in a research report on Thursday, September 17th. They set a “buy” rating and a $7.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $6.00.
Read Our Latest Research Report on iBio
iBio Price Performance
NASDAQ IBIO opened at $0.76 on Friday. The business has a 50 day simple moving average of $0.99 and a 200 day simple moving average of $1.63. iBio has a one year low of $0.69 and a one year high of $3.82. The stock has a market capitalization of $49.01 million, a P/E ratio of -2.72 and a beta of 1.47.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in iBio in the third quarter worth approximately $29,000. Headlands Technologies LLC grew its stake in iBio by 333.0% in the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after acquiring an additional 36,463 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of iBio during the third quarter valued at approximately $105,000. Bank of America Corp DE increased its holdings in shares of iBio by 150.8% during the first quarter. Bank of America Corp DE now owns 290,413 shares of the company’s stock valued at $552,000 after acquiring an additional 174,620 shares in the last quarter. Finally, Noesis Capital Mangement Corp raised its position in shares of iBio by 38.9% during the first quarter. Noesis Capital Mangement Corp now owns 311,500 shares of the company’s stock worth $592,000 after purchasing an additional 87,300 shares during the period. 7.90% of the stock is owned by institutional investors and hedge funds.
iBio Company Profile
iBio, Inc. (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases. iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.
See Also
- Five stocks we like better than iBio
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
